Back to Stocks

NTLA

Intellia Therapeutics, Inc.
2 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Intellia Therapeutics is rapidly transitioning from a clinical-stage entity to a commercial-ready biopharmaceutical leader.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the clinical optimism, Intellia's financial profile remains precarious, characterized by a substantial accumulated deficit of $2.69 billion and a continued reliance on equity markets.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every NTLA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q reveals a company at a critical inflection point, balancing breakthrough clinical success against the harsh realities of commercial scaling. The positive Phase 3 data for lonvo-z provides a clear path to revenue, yet the transition to a commercial entity is capital-intensive. The recent equity raise and the reduction in R&D spend suggest a pivot toward execution, but the substantial lease liabilities and ongoing litigation introduce variables that could impact the timeline for profitability. Ultimately, the investment case for Intellia now hinges on the successful navigation of the BLA process and the subsequent commercial launch of lonvo-z. While the balance sheet is currently sufficient to reach 2028, the company's ability to manage its high burn rate while scaling a first-of-its-kind CRISPR therapy will determine if it can achieve a sustainable valuation re-rating or if it will require further dilutive financing to survive the launch phase.

Selected Quarter

Core Takeaway

Intellia has validated its lead HAE asset with Phase 3 success, but must now manage a high-burn transition to a commercial-stage company.

Investor Lens

The trade-off is between the high-probability clinical success of lonvo-z and the financial risk of a pre-revenue company scaling commercial infrastructure.

Watch Next

Completion of the BLA submission in the second half of 2026 and FDA acceptance.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.30Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 11

Secured $194.6 million in net proceeds from a public offering in April 2026.

capital raise
70%
bearishMay 11

Continued high operating losses with a net loss of $96.2 million in Q1.

margin compression
60%
bullishMay 11

FDA lifted clinical holds on nex-z Phase 3 trials, allowing patient screening to advance.

regulatory action
80%
bullishMay 11

Secured $194.6 million in net proceeds from a public offering in April 2026.

capital raise
70%
bearishMay 11

Continued high operating losses with a net loss of $96.2 million in Q1.

margin compression
60%
bullishMay 11

FDA lifted clinical holds on nex-z Phase 3 trials, allowing patient screening to advance.

regulatory action
80%

Filing History

10-QMay 11, 2026
Expand Sequence

The latest 10-Q reveals a company at a critical inflection point, balancing breakthrough clinical success against the harsh realities of commercial scaling. The positive Phase 3 data for lonvo-z provides a clear path to revenue, yet the transition to a commercial entity is capital-intensive. The recent equity raise and the reduction in R&D spend suggest a pivot toward execution, but the substantial lease liabilities and ongoing litigation introduce variables that could impact the timeline for profitability. Ultimately, the investment case for Intellia now hinges on the successful navigation of the BLA process and the subsequent commercial launch of lonvo-z. While the balance sheet is currently sufficient to reach 2028, the company's ability to manage its high burn rate while scaling a first-of-its-kind CRISPR therapy will determine if it can achieve a sustainable valuation re-rating or if it will require further dilutive financing to survive the launch phase.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.